Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLQVTJ)

Drug Name
Octopamine Drug Info
Synonyms
Analet; Norden; Norfen; Norphen; Norsympathol; Norsympatol; Norsynephrine; Octapamine; Octopamin; Octopamina; Octopaminum; Octopamina [Spanish]; Octopamine [INN]; Octopamine hydrochloride; Octopaminum [Latin]; Paraoxyphenyl aminoethanol; ND 50; TBB066518; WIN 5512; WV 569; Beta-hydroxytyramine; Octopamina [INN-Spanish]; Octopaminum [INN-Latin]; P-Hydroxyphenylethanolamine; P-Norsynephrin; P-Octopamine; Para-Octopamine; Alpha-Aminoethyl-4-hydroxybenzylalkohol; Alpha-(Aminoethyl)-4-hydroxybenzenemethanol; Alpha-(Aminoethyl)-p-hydroxybenzyl alcohol; Alpha-(Aminomethyl)-p-hydroxybenzyl alcohol; Alpha-(aminomethyl)-4-hydroxybenzenemethanol; 1-(p-Hydroxyphenyl)-2-aminoethanol; 4-(2-Amino-1-hydroxyethyl)phenol; 4-Octopamine
Indication
Disease Entry ICD 11 Status REF
Thrombosis DB61-GB90 Discontinued in Phase 2a [1]
Cross-matching ID
PubChem CID
4581
ChEBI ID
CHEBI:17134
CAS Number
CAS 104-14-3
TTD Drug ID
DMLQVTJ
INTEDE Drug ID
DR1184

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Coagulation factor Xa (F10)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apixaban DM89JLN Thrombosis DB61-GB90 Approved [8]
Rivaroxaban DMQMBZ1 Deep vein thrombosis BD71 Approved [9]
DU-176b DMCIJBH Atrial fibrillation BC81.3 Approved [10]
Emicizumab DM0AQ83 Factor VIII deficiency 3B10 Approved [11]
BETRIXABAN DM2C4RF Venous thromboembolism BD72 Approved [12]
Lmw heparin DMJPD06 Coagulation defect 3B10.0 Approved [13]
Nadroparin calcium DMBNKST Coagulation defect 3B10.0 Approved [14]
Fondaparinux sodium DMWS3FH Deep vein thrombosis BD71 Approved [15]
Danaparoid DM6CLBN Deep venous clot BD71 Approved [16]
Coagulation Factor IX DM8HBJI Haemophilia B 3B11.0 Approved [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [18]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [19]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [20]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [21]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [22]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [23]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [24]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [25]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [19]
Verapamil DMA7PEW Angina pectoris BA40 Approved [26]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By RNA cytidine acetyltransferase (hALP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Folic Acid DMEMBJC Colorectal carcinoma Approved [27]
Caffeine DMKBJWP Allergic rhinitis CA08.0 Approved [28]
Procainamide DMNMXR8 Ventricular arrhythmias BC71 Approved [29]
Sulfamethoxazole DMB08GE Acute otitis media AB00 Approved [30]
Sulfadiazine DMTW3R8 Rheumatic fever 1B40-1B42 Approved [31]
Tobramycin DMUI0CH Bacteremia 1A73 Approved [32]
Mesalazine DMOL5IU Diverticulitis Approved [33]
Allopurinol DMLPAOB Gout FA25 Approved [34]
Netilmicin DMRD1QK Bacterial infection 1A00-1C4Z Approved [35]
Clonazepam DMTO13J Absence epilepsy Approved [36]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [37]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [38]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [39]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [22]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [26]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [40]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [41]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [42]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [43]
Propranolol DM79NTF Angina pectoris BA40 Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [45]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [46]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [47]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [48]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [49]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [50]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [51]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [52]
Verapamil DMA7PEW Angina pectoris BA40 Approved [53]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Trace amine-associated receptor 1 (TAAR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TRYPTAMINE DMAFPHB N. A. N. A. Phase 3 [7]
PHENETHYLAMINE DMX0G4F Discovery agent N.A. Investigative [7]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor Xa (F10) TTCIHJA FA10_HUMAN Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [3]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [4]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [5]
RNA cytidine acetyltransferase (hALP) DEZV4AP NAT10_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Trace amine-associated receptor 1 (TAAR1) OTUY8CGM TAAR1_HUMAN Gene/Protein Processing [7]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2149).
2 Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost. 2009 Jul;7(7):1143-51.
3 Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults. J Clin Pharmacol. 2001 Oct;41(10):1059-63.
4 Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun. 1998 Aug 28;249(3):838-43.
5 Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol. 2005 Oct;29(7):590-8.
6 [N-acetylation of biogenic amines in Drosophila virilis]. Genetika. 1997 Jun;33(6):788-92.
7 Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands. Biochem J. 2009 Oct 23;424(1):39-45. doi: 10.1042/BJ20090998.
8 Pfizer. Product Development Pipeline. March 31 2009.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
11 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
12 Company report (Portola)
13 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
14 Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
15 Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
16 Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
17 Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.
18 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
19 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
20 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
21 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
22 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
23 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
24 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
25 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
26 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
27 Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol. 1992 Sep 25;44(6):1099-104.
28 A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther. 1993 Aug;54(2):134-41.
29 Effect of H2-receptor antagonists on rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity. Drug Metab Dispos. 1992 Jan-Feb;20(1):74-8.
30 Crystallization and preliminary X-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Oct 1;63(Pt 10):862-4.
31 Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
32 Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6'-N-acetyltransferase Ib and IIa proteins. J Bacteriol. 1992 May;174(10):3196-203.
33 NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol. 2008 Mar;46(3):259-65.
34 Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol. 1999 Jan;54(11):869-76.
35 Aminoglycoside resistance resulting from tight drug binding to an altered aminoglycoside acetyltransferase. Antimicrob Agents Chemother. 2003 May;47(5):1577-83.
36 Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan;1(1):3-5.
37 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
38 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
39 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
40 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
41 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
42 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
43 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
44 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
45 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
46 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
47 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
48 Drug Interactions Flockhart Table
49 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
50 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
51 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
52 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
53 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.